BioCryst Pharmaceuticals, Inc. (BCRX)
BCRX Stock Price Chart
Explore BioCryst Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze BCRX price movements and trends.
BCRX Company Profile
Discover essential business fundamentals and corporate details for BioCryst Pharmaceuticals, Inc. (BCRX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
4 Mar 1994
Employees
580.00
Website
https://www.biocryst.comCEO
Jon P. Stonehouse
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
BCRX Financial Timeline
Browse a chronological timeline of BioCryst Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 May 2026
Upcoming earnings on 23 Feb 2026
Upcoming earnings on 3 Nov 2025
EPS estimate is $0.03, while revenue estimate is $162.24M.
Earnings released on 4 Aug 2025
EPS came in at $0.15 surpassing the estimated $0.03 by +400.00%, while revenue for the quarter reached $163.35M , beating expectations by +9.20%.
Earnings released on 5 May 2025
EPS came in at $0.00 surpassing the estimated -$0.07 by +100.21%, while revenue for the quarter reached $145.53M , missing expectations by -2.80%.
Earnings released on 24 Feb 2025
EPS came in at -$0.13 falling short of the estimated -$0.07 by -85.71%, while revenue for the quarter reached $131.53M , beating expectations by +3.87%.
Earnings released on 4 Nov 2024
EPS came in at -$0.07 matching the estimated -$0.07, while revenue for the quarter reached $117.09M , missing expectations by -8.33%.
Earnings released on 5 Aug 2024
EPS came in at -$0.06 surpassing the estimated -$0.19 by +68.42%, while revenue for the quarter reached $109.33M , beating expectations by +11.20%.
Earnings released on 6 May 2024
EPS came in at -$0.17 surpassing the estimated -$0.23 by +26.09%, while revenue for the quarter reached $92.76M , beating expectations by +8.37%.
Earnings released on 26 Feb 2024
EPS came in at -$0.28 falling short of the estimated -$0.24 by -16.67%, while revenue for the quarter reached $93.40M , beating expectations by +3.77%.
Earnings released on 2 Nov 2023
EPS came in at -$0.19 surpassing the estimated -$0.25 by +24.00%, while revenue for the quarter reached $86.74M , beating expectations by +0.92%.
Earnings released on 3 Aug 2023
EPS came in at -$0.24 surpassing the estimated -$0.25 by +4.00%, while revenue for the quarter reached $82.49M , beating expectations by +1.85%.
Earnings released on 3 May 2023
EPS came in at -$0.28 surpassing the estimated -$0.30 by +6.67%, while revenue for the quarter reached $68.78M , missing expectations by -4.05%.
Earnings released on 21 Feb 2023
EPS came in at -$0.38 falling short of the estimated -$0.19 by -100.00%, while revenue for the quarter reached $79.55M , beating expectations by +5.74%.
Earnings released on 1 Nov 2022
EPS came in at -$0.23 surpassing the estimated -$0.32 by +28.13%, while revenue for the quarter reached $75.83M , beating expectations by +1.40%.
Earnings released on 4 Aug 2022
EPS came in at -$0.32 surpassing the estimated -$0.36 by +11.11%, while revenue for the quarter reached $65.53M , beating expectations by +3.48%.
Earnings released on 5 May 2022
EPS came in at -$0.40 falling short of the estimated -$0.39 by -2.56%, while revenue for the quarter reached $49.92M , missing expectations by -2.80%.
Earnings released on 23 Feb 2022
EPS came in at -$0.40 falling short of the estimated -$0.31 by -29.03%, while revenue for the quarter reached $47.16M , missing expectations by -7.65%.
Earnings released on 3 Nov 2021
EPS came in at -$0.33 falling short of the estimated -$0.30 by -10.00%, while revenue for the quarter reached $40.99M , beating expectations by +1.92%.
Earnings released on 5 Aug 2021
EPS came in at -$0.24 falling short of the estimated -$0.22 by -9.09%, while revenue for the quarter reached $49.96M , beating expectations by +74.26%.
Earnings released on 6 May 2021
EPS came in at -$0.36 falling short of the estimated -$0.26 by -38.46%, while revenue for the quarter reached $19.06M , beating expectations by +260.28%.
Earnings released on 25 Feb 2021
EPS came in at -$0.34 falling short of the estimated -$0.25 by -36.00%, while revenue for the quarter reached $4.02M , missing expectations by -77.08%.
Earnings released on 5 Nov 2020
EPS came in at -$0.26 falling short of the estimated -$0.25 by -4.00%, while revenue for the quarter reached $6.10M , beating expectations by +396.18%.
BCRX Stock Performance
Access detailed BCRX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.